About SolveBio
SolveBio is a Healthcare company based in New York (United States) founded in 2013 by David Gross, and was acquired by Quartz Bio in January 2023. Genomic data analytics platform is provided for precision medicine. SolveBio has raised $2 million across 3 funding rounds from investors including NIH, Quartz Bio and NIH SBIR/STTR. Its focus areas include Life Sciences, Genomics, Genome Informatics and Integrative Bioinformatics Platforms. Its competitors include Helix, Benchling and Genuity Science; 3 of its 3 listed competitors have raised funding.
Company details
SolveBio was founded in 2013 in New York, United States, focusing on the biotechnology sector. Advanced data analytics for precision medicine are delivered across therapeutic development stages. Complex molecular data access is enabled without barriers, supporting translational and clinical teams in applying analytic tools, machine learning algorithms, and big data platforms for operational efficiency.
- Headquarters New York, United States
- Founders David Gross
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website solvebio.com
- Social LinkedIn X Facebook
- Acquired by Quartz Bio (Jan 2023)
- Total Equity Funding$2M (USD)
in 3 rounds
- Latest Funding Round$1.5M (USD), Grant
Jan 2018
- InvestorsNIH
& 6 more
- Acquired byQuartz Bio
(Jan 2023)
Funding Insights of SolveBio
SolveBio has successfully raised a total of $2M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.5 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2M
- Total Rounds 3
- Last Round Grant — $1.5M
- First Round $2M
(May 2014)
- Investors Count 6
All 3 funding rounds of SolveBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2018 | $1.5M | Grant | – | – | |
| Jun 2016 | $223,181 | Grant | – | – | |
| May 2014 | $2M | Seed | – | – |
7 investors in total: 6 institutional and 1 angel.
Investors in SolveBio
SolveBio has secured backing from 7 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include NIH, Quartz Bio and NIH SBIR/STTR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| sbir.nih.gov | ||||
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
Early-stage investments are provided to transformative technology companies. | svangel.com | San Francisco, United States | ||
Investments are directed toward early-stage consumer-tech startups. | scifi.vc | San Francisco, United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
ML Max Levchin | Co-founder of PayPal, Affirm CEO, prominent tech investor | unknown_fd83bf622c9c41dfb | ||
Biomarker data from clinical trials is analyzed by Quartz Bio. | 2012 | quartz.bio | Geneva, Switzerland |
Investor details for SolveBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SolveBio
10 people are tracked at SolveBio (5 in leadership, 3 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
David Gross | Co-Founder | Leadership |
Mark Kaganovich | CEO | Leadership |
Dandan Xu | Chief Scientific Officer | Leadership |
David Caplan | Chief Technical Officer | Leadership |
Gopal Ramachandran | Head of Machine Learning | Leadership |
Stephen Wolfram | Advisor | Board & advisors |
Joel Dudley | Advisor | Board & advisors |
Yaniv Erlich | Advisor | Board & advisors |
David Park | Computer Systems Analyst | Team |
Sarah Brooks | Data Specialist Contractor | Team |
Complete people profiles for SolveBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SolveBio
4 dated milestones of SolveBio across 10 years, from founding to its latest funding, stage changes and deals.
- Founded SolveBio is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Grant, of $1.5M.
- Exit Acquired by Quartz Bio.
Competitors of SolveBio
SolveBio has 3 listed competitors in our database, 3 of them funded. They include Helix, Benchling and Genuity Science.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| helix.com | 2015 | San Francisco, United States | $435M | Genomic database for clinical research is provided. | ||
| benchling.com | 2012 | San Francisco, United States | $411.9M | 640 | Cloud-based bioinformatics platform is offered for biotech research. | |
| genuitysci.com | 2013 | Boston, United States | $515M | AI-based omics data analysis solutions are provided to researchers. |
Detailed competitors of SolveBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SolveBio
Websites that share an audience with SolveBio (solvebio.com).
Websites whose visitors overlap most with SolveBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bio-itworld.com | 100% | #1,672,238 | View details | ||
| flatiron.com | 60% | 561.6K | #96,877 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as SolveBio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Solvebio
Complete news archive for SolveBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SolveBio
SolveBio was founded in 2013 and raised its 1st funding round 1 year after it was founded.
SolveBio is headquartered in New York, United States. It is registered at New York, New York, United States.
SolveBio is a funded company, having raised a total of $2M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on May 2014.
SolveBio was founded in 2013 in New York, United States, focusing on the biotechnology sector. Advanced data analytics for precision medicine are delivered across therapeutic development stages. Complex molecular data access is enabled without barriers, supporting translational and clinical teams in applying analytic tools, machine learning algorithms, and big data platforms for operational efficiency.
SolveBio's top competitors include Helix, Benchling and Genuity Science.
SolveBio has 7 investors. Key investors include NIH, Quartz Bio, NIH SBIR/STTR, Max Levchin, and Andreessen Horowitz.
Yes. SolveBio was acquired by Quartz Bio in January 2023.